Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia

Genomic Classification and Prognosis in Acute Myeloid Leukemia

(2016) Elli Papaemmanuil et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myelodysplastic syndromes: Contemporary review and how we treat

(2015) Naseema Gangat et al.   AMERICAN JOURNAL OF HEMATOLOGY

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia

(2014) Aristoteles Giagounidis et al.   CANCER

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine

(2014) Tobias Svensson et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Induction of short-term remission with single agent eltrombopag in refractory nucleophosmin-1-mutated acute myeloid leukemia

(2014) U. Platzbecker et al.   HAEMATOLOGICA

Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug

(2013) R. Desmond et al.   BLOOD

Clinical and biological implications of driver mutations in myelodysplastic syndromes

(2013) E. Papaemmanuil et al.   BLOOD

Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

(2013) T Haferlach et al.   LEUKEMIA

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation

(2012) M. Roth et al.   BLOOD

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study

(2012) M. N. Saleh et al.   BLOOD

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine

(2012) Peter L. Greenberg et al.   LEUKEMIA & LYMPHOMA

Eltrombopag and Improved Hematopoiesis in Refractory Aplastic Anemia

(2012) Matthew J. Olnes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis

(2012) Hongliang Sun et al.   Stem Cell Research

Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy

(2010) H. M. Kantarjian et al.   BLOOD

Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study

(2010) Gregory Cheng et al.   LANCET

Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome

(2009) B. Will et al.   BLOOD

Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes

(2009) Judith Neukirchen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Preclinical Activity of Eltrombopag (SB-497115), an Oral, Nonpeptide Thrombopoietin Receptor Agonist

(2008) Connie L. Erickson-Miller et al.   STEM CELLS